Medicamentsen-ligne vous propose les traitements dont vous avez besoin afin de prendre soin de votre santé sexuelle. Avec plus de 7 ans d'expérience et plus de 90.000 clients francophones, nous étions la première clinique fournissant du acheter levitra original en France à vente en ligne et le premier vendeur en ligne de Viagra dans le monde. Pourquoi prendre des risques si vous pouvez être sûr avec Medicamentsen-ligne - Le service auquel vous pouvez faire confiance.


Clinical Psychology Review 26 (2006) 17 – 31 The empirical status of cognitive-behavioral therapy: Andrew C. Butler a,*, Jason E. Chapman b, Evan M. Forman c, Aaron T. Beck a a University of Pennsylvania and the Beck Institute for Cognitive Therapy and Research, United States b Medical University of South Carolina, United States Received 20 September 2004; received in revised form 7 June 2005; accepted 5 July 2005 This review summarizes the current meta-analysis literature on treatment outcomes of CBT for a wide range of psychiatric disorders. A search of the literature resulted in a total of 16 methodologically rigorous meta-analyses. Our review focuses on effectsizes that contrast outcomes for CBT with outcomes for various control groups for each disorder, which provides an overview ofthe effectiveness of cognitive therapy as quantified by meta-analysis. Large effect sizes were found for CBT for unipolardepression, generalized anxiety disorder, panic disorder with or without agoraphobia, social phobia, posttraumatic stress disorder,and childhood depressive and anxiety disorders. Effect sizes for CBT of marital distress, anger, childhood somatic disorders, andchronic pain were in the moderate range. CBT was somewhat superior to antidepressants in the treatment of adult depression. CBTwas equally effective as behavior therapy in the treatment of adult depression and obsessive-compulsive disorder. Largeuncontrolled effect sizes were found for bulimia nervosa and schizophrenia. The 16 meta-analyses we reviewed support theefficacy of CBT for many disorders. While limitations of the meta-analytic approach need to be considered in interpreting theresults of this review, our findings are consistent with other review methodologies that also provide support for the efficacy CBT.
D 2005 Elsevier Ltd. All rights reserved.
Cognitive-behavioral therapy is one of the most extensively researched forms of psychotherapy. Over 120 controlled clinical trials were added to the literature in the eight years between 1986 and 1993 (1994) and this proliferation has continued (There are now over 325 published outcome studies oncognitive-behavioral interventions. This growth is due in part to the ongoing adaptation of CBT for an increasinglywider range of disorders and problems (Yet, many questions remain regarding theoverall effectiveness of CBT, its differential effectiveness by disorder, the nature of the control groups by which itseffectiveness has been established, and the extent to which its effects persist following the cessation of treatment. Inthis paper we review evidence from meta-analyses that address these questions. Our approach is unique in that wesystematically summarize findings across high-quality meta-analyses for 16 different disorders. We focus on directcomparisons of CBT to alternative treatments wherever possible.
A review of meta-analyses on CBT outcomes is particularly relevant to the ongoing debate about the comparative efficacy of different treatments (For instance, a recent review of meta-analyses and * Corresponding author. Tel.: +1 831 372 3910; fax: +1 866 752 4401.
E-mail address: (A.C. Butler).
0272-7358/$ - see front matter D 2005 Elsevier Ltd. All rights reserved.
doi:10.1016/j.cpr.2005.07.003 A.C. Butler et al. / Clinical Psychology Review 26 (2006) 17–31 primary studies on CBT for depression concludes that the effectiveness of CBT has been overstated in the literature(The question of whether a particular psychotherapy is superior to others has producedardent controversy. The null hypothesis, that all therapies are equally effective, has been dubbed the Dodo Birdverdict (from a line in Alice in Wonderland, bAll have won and all must have prizesQ). Proponents of the Dodo Birdverdict (e.g., meta-analytic evidence to support their claim(bthe verdict is inQ). Others have taken exception, arguing that the way in which meta-analysis has been used toaddress this question has lead to a false, or at least premature verdict (,Krause, Saunders, & Kopta, 1997). The methodological problem at the center of this particular argument involves thepractice of aggregating the outcomes for all treatments across all disorders into one meta-analysis. This approachpotentially obscures real differences between specific treatments for specific disorders. The present report addressesthis problem by reviewing meta-analytic evidence of the comparative efficacy of alternative treatments withindisorders.
In addition to comparative efficacy, key questions exist regarding the long-term effectiveness of CBT, i.e., the extent to which intervention effects persist following the cessation of treatment. Related to this is whether these effectspersist to a greater extent than do those of other treatments. Evidence suggests that the effects of psychological andespecially psychopharmacological interventions substantially weaken, if not disappear entirely, once the activetreatment is discontinued (e.g., However, given CBT’s focus on modifyingthinking and transferring the skills learned in therapy to everyday life (i.e., making the patient his/her own therapist),treatment effects would be expected to persist following termination (Indeed, several clinical trials havepointed toward CBT’s long-term effectiveness and prevention of relapse (e.g., ,1984). The current review aims to determine the extent to which meta-analytic support exists for these importantquestions regarding the long-term effects of CBT.
Finally, two recent review articles have focused on the question of CBT’s superiority to alternative treatments for depression (In the present report we provide alarger context within which to interpret these reviews.
Meta-analysis has gained increasing recognition as a useful way to evaluate the efficacy of a treatment and has certain advantages as well as limitations as a review method (In meta-analysis, treatment efficacy is quantified in terms of an effect size (ES). An ES indicates the magnitude of an observedeffect in a standard unit of measurement (e.g., a standard deviation or correlation coefficient). Effect sizes have beencategorized along a continuum of no effect (ES b 0.2), low (0.2 V ES b 0.5), medium (0.5 V ES b 0.8) and high(ES z 0.8) (Hence, the strength of meta-analysis comes from the use of a standardized unit to compareoutcomes from studies that may use different measures. Also, by averaging effect sizes across different studies andcomparisons, meta-analysis increases the effective sample size and minimizes the influence of extraneous factors.
This allows for a more precise evaluation of the efficacy of a treatment.
Meta-analysis is not without its limitations. One problem involves the number of comparisons included from each primary study in a meta-analysis. Some studies may report numerous comparisons and other studies few orone. Thus, findings from studies with many comparisons may be given inordinated weight in a meta-analysis. Inour review we report the number of comparisons covered in each meta-analysis. Another possible limitation ofmeta-analysis is inattention to possible moderator variables (e.g. gender differences). When moderator variables canbe identified and the sample of studies on a disorder is large enough, meta-analysis researchers may include themin their analysis. An important example of a moderator variable is the effect of researcher allegiance in outcomestudies on unipolar depression. We include findings on the effect on researcher allegiance in this review. A finallimitation, which also derives from inattention to study differences, is that striking successes and failures may beoverlooked. Such successes and failures may be important for guiding future theoretical development and empiricalstudy. In this review we report on emerging trends in outcome studies and suggest areas for further investigation.
Our first objective was to identify published meta-analyses that reviewed outcome studies on cognitive-behavioral therapy. When there were multiple meta-analyses for the same disorder we selected the most extensive andmethodologically rigorous meta-analysis. Typically, this was also the most recent meta-analysis. Methodologicalstrengths we looked for were (1) inclusion of only randomized clinical trials, (2) sample-size weighting of effect sizes, A.C. Butler et al. / Clinical Psychology Review 26 (2006) 17–31 (3) analysis of heterogeneity of effect sizes and outliers, and (4) inclusion of moderator variables in analyses. Thesefactors took precedence over the mere number of studies contained in a meta-analysis.
The identification of meta-analyses began with a search of the computer databases PsycINFO, Eric, and Medline from 1967 to July 2004 using the key terms bcognitive therapyQ, bcognitive-behavioralQ and bmeta-analysisQ. Weincluded the term cognitive therapy since this form of treatment typically incorporates behavioral interventions. Theresulting list of articles and book chapters was retrieved and reviewed. Additional meta-analyses were identified in thetexts of these reviews and a second series of articles and book chapters were retrieved. The 34 reviews thus identifiedwere then culled based on several criteria. Three meta-analyses were excluded because they were written in alanguage other than English. Ten were excluded because they were superseded by more extensive or methodolog-ically rigorous reviews of the same literature. Six were excluded because they did not clearly distinguish CBT fromother psychosocial interventions, one because it addressed process variables rather than outcome, and one because itdid not focus on any specific disorder.
The final sample comprised 16 meta-analyses that included collectively 9995 subjects in 332 studies. These meta- analyses included 562 comparisons covering 16 disorders or populations: adult unipolar depression, adolescentunipolar depression, generalized anxiety disorder, panic disorder with or without agoraphobia, social phobia,obsessive-compulsive disorder, posttraumatic stress disorder, schizophrenia, marital distress, anger, bulimia, inter-nalizing childhood disorders (including depressive, anxious, and somatic disorders), sexual offending, and chronicpain (not headache).
A defining feature of cognitive-behavioral therapy is the proposition that symptoms and dysfunctional behaviors are often cognitively mediated and, hence, improvement can be produced by modifying dysfunctional thinking andbeliefs (CBT can be contrasted with purely behavioral treatments in which cognition is notconsidered an important explanatory variable and is not identified as a specific target for intervention. In the meta-analyses we review, there were occasionally comparisons in which studies on CBT and studies on behavior therapywere combined for analysis. When this was the case, we re-calculated the effect size for the particular comparisonexcluding the purely behavioral studies.
A few of the selected meta-analyses overlapped in terms of the studies reviewed. In these cases, we included the pertinent studies from only one meta-analysis. A single exception to this occurred where the same studies wereexamined in two different meta-analyses but with regard to different comparisons. meta-analyzed studies comparing CT of panic disorder with alternative treatments and control groups. and Devilly (1999) examined many of the same studies but compared patients’ outcome and follow-up scores againstcommunity norms. We reviewed each meta-analysis in reference to its unique comparisons.
We have used certain conventions in reporting the findings from each meta-analysis. For instance, effect sizes are sometimes categorized as bcontrolledQ versus buncontrolledQ (A controlled ESexpresses the magnitude of a specific treatment effect as compared to alternative treatments or control conditions. Itis calculated by subtracting the post-treatment mean of the control group from the post-treatment mean of thetreatment group and dividing by the standard deviation of the control group (r bythe pooled standard deviation (Hence, a controlled ES of 0.50 would indicate that the mean outcomescore of the treatment group was one-half a standard deviation larger than the mean outcome score of the controlgroup.
An buncontrolledQ effect size expresses the amount of improvement within a group from pretreatment to post- treatment. It is calculated by subtracting a group’s post-treatment mean from its pretreatment mean and dividing bythe pooled standard deviation. Uncontrolled effect sizes are less preferable than controlled effect sizes since they aresusceptible to threats to internal validity (e.g., the effects of maturation, history, regression to the mean). Twelve of themeta-analyses included in this review report controlled sample-size weighted effect sizes. Three meta-analyses(covering obsessive-compulsive disorder, schizophrenia, and bulimia nervosa) include only uncontrolled effectsizes. These were included in this review to provide at least some indication of treatment efficacy where therewas no controlled meta-analysis available for a disorder. We denote uncontrolled effect sizes as ESu.
To facilitate interpretation, we also report U3 scores for each comparison. U3 represents the percentage of the scores in the lower-meaned group that was exceeded by the average score in the higher-meaned group (The relationship between ES and U3 is important to understand when interpreting the findings from meta-analyses.
For example, an ES of 0.0 would indicate no treatment effect. It converts into a U3 of 50%, which in this reviewwould indicate that the average CT patient did as well as the average control group member. A controlled ES of 1.0 A.C. Butler et al. / Clinical Psychology Review 26 (2006) 17–31 would represent a blargeQ treatment effect and would translate into a U3 of 84%, indicating that the average CT patienthad an outcome superior to that of 84% of the control group. Conversely, an ES of À 1.0 would represent a blargeQeffect in the opposite direction. In this case, U3 would again be 84% but it would indicate that the average controlpatient had an outcome superior to 84% of the CT group.
Meta-analytic findings were not available for some disorders. Where possible, we have included a description of the findings and conclusions of recent comprehensive qualitative review papers. However, these results should beconsidered preliminary, and future meta-analyses will be required to fully address the primary questions of thisreview.
Teach meta-analysis along with average effect sizes and U3 statistics for specific comparisons. These findings are discussed below by disorder. In some cases we refer to previous meta-analyses not listed in Tillustrate important historical trends. We also refer to findings from single studies where appropriate.
CBT for depression has been studied in over 75 clinical trials since 1977 ( Blackburn, 1998). meta-analyses and primary studies in this area and concluded thatCBT is not as effective as proponents of the therapy suggest. However, they excluded from their review high-quality clinical trials showing cognitive-behavioral therapy to be superior to alternative treatments at follow-up(see a comparison with psychodynamic therapy; for a comparison with antidepressant medication). Since Parker et al. did not report the criteria by which theyselected research studies for their review, it is difficult to interpret their conclusions. thefirst meta-analysis on this topic and found CT to be superior to untreated controls, wait list, pharmacotherapy,behavior therapy, and a heterogeneous group other therapies. hypothesized that Dobson’s findings were positively biased toward CBT by researcher allegiance; the tendencyfor authors to prefer one therapy to another. They reanalyzed the same set of studies reviewed by Dobson whilecontrolling for researcher allegiance and found that researcher allegiance accounted for half the difference betweenCBT and other treatments. They also analyzed a later set of 37 studies on CBT for depression and found noevidence of researcher allegiance. A possible explanation for the difference in findings is that researcher allegianceinfluences study outcomes when a new treatment is first tested, but its influence fades over time. In the secondanalysis, CBT was still found to be superior to waiting list, attentional controls, and a group of other variouspsychotherapies.
the most extensive and methodologically rigorous meta-analysis on CBT for depression to date. Their findings are displayed at the top of Twas found to be superior when comparedwith waiting list or placebo controls. Since waiting list and placebo conditions are not equivalent, future meta-analyses should evaluate comparisons of CBT with each of these conditions separately (Thedifference between CBT and behavior therapy was not statistically significant. Although some of the studiescomparing CBT with behavior therapy were done with non-clinical samples, findings for clinical and non-clinicalsamples led to the same conclusion of treatment equivalence.
compared CBT to a group of therapies categorized as miscellaneous and found that CBT was modestly superior (ES = 0.24). out that some of the therapies in theGloaguen et al.’s miscellaneous category (e.g., progressive muscular relaxation) do not represent comprehensivetreatments for depression. Based on criteria that they developed, Wampold et al. further categorized thesemiscellaneous therapies into bona fide and non-bona fide therapies for depression. They then compared CBT tothe group of therapies they identified as bona fide and found that CBT was only marginally superior (ES = 0.16,p b .06).
A comparison of CBT (or any psychotherapy) with a control group consisting of a heterogeneous collection of miscellaneous therapies, as done by Gloaguen et al., can at best provide limited information. Future meta-analysesare needed that provide direct comparisons between CBT and specific alternative therapies. Due to the largenumber of practitioners of psychodynamic therapy, comparisons between CBT and psychodynamic therapy for A.C. Butler et al. / Clinical Psychology Review 26 (2006) 17–31 Table 1Meta-analyses of cognitive therapy outcomes Mood and feelings questionnaire Relaxation Mood and Feelings Questionnaire Relaxation at follow-up (3 months) Supportive therapy at follow-up (3 months) Panic disorder with or without agoraphobia post-treatment to follow-up (meanfollow-up interval = 12.6 months) Obsessive-compulsive symptoms: Reduction from pre- to post-treatment A.C. Butler et al. / Clinical Psychology Review 26 (2006) 17–31 Obsessive-compulsive symptoms: Reduction from pre- to post-treatment Posttraumatic stress disorderNational Collaborating Centre 14 Total symptoms (various clinician Reduction from pre- to post-treatment A.C. Butler et al. / Clinical Psychology Review 26 (2006) 17–31 (not including behavior therapy orbiofeedback) Positive ES scores indicate superiority of cognitive therapy over the comparison group. Negative ES scores indicate superiority of the comparisongroup over cognitive therapy. U3 represents the percentage of subjects in the inferior group whose outcome scores were exceeded by the averagesubject in the superior group. Subscript duT denotes an uncontrolled effect size.
a In these analyses only, a negative effect size indicates symptom scores below community norms. A positive effect size indicates symptom scores b Relative risk (RR) is used as the index of effect size in these comparisons. For dichotomous outcomes, RR is the ratio of the treatment event to the control event. An RR of 1 indicates no difference between treatment and control conditions. An RR of 0.75 indicates that the event rateassociated with CT is three-quarters of that with the control condition, or in other words, the relative risk reduction is 25. No U statistic is reportedfor these effect sizes since RR is as intuitively interpretable as U.
depression are of particular interest. There are relatively few direct comparisons and not enough to provide thebasis for a meaningful meta-analysis. Two large well-controlled trials have been conducted. The first was theTreatment of Depression Collaborative Research Project (TDCRP) conducted in the 1980s. This study comparedthe efficacy of CBT, interpersonal psychotherapy, and pharmacotherapy for depression. Outcomes for CBT andinterpersonal therapy were generally equivalent (although CBT did not fare as well as IPT orantidepressant medication among the more severely depressed patients in this study. In the 1990s, Shapiro et al.
conducted a major study comparing the efficacy of CBT and psychodynamic-interpersonal (PIT) for depression.
This study also experimentally manipulated the duration of treatment (8 sessions versus 16 sessions). At the end oftreatment CBT and PIT were equally effective (However, 1 year after completing treatment,patients who had received 8 sessions of PIT did worse on almost all measures compared with the other threetreatment conditions (8-session CBT, 16-session PIT, and 16-session CBT).
The intervention for depression that is most widely used in the United States is antidepressant medication (that CBT was significantly better than antidepressantmedication. This conclusion may overstate the case for CBT since some earlystudies comparing CT with medications, which had methodological features that favored CT. One study (Beck, Kovacs, & Hollon, 1977) started tapering medications 1 week prior to the end of therapy, and anotherstudy (was an effectiveness study in which the comparisongroup showed an unusually low response to medication. More recently, however, a major high-quality controlledtrial comparing CT with a commonly prescribed serotonin reuptake inhibitor (paroxetine) found that cognitivetherapy was equally effective for the initial treatment of moderate to severe major depression (2005).
The combination of cognitive and pharmacotherapy for depression is widely practiced in the community. In their narrative review, ed that the combination of CT and pharmacotherapy has typicallybeen associated with a small (0.25 standard deviation) advantage over either modality alone. There is some evidencethat the combination of psychotherapy and antidepressant medication leads to significantly better outcomes withseverely depressed patients (However, the Thase et al. analysis aggregated several forms of A.C. Butler et al. / Clinical Psychology Review 26 (2006) 17–31 psychotherapy. The question of whether adding medication to CBT for severely depressed patients leads tosignificantly better outcomes has not yet been the subject of a meta-analysis.
Given the potentially marginal differences in outcome between single versus combination treatments, and the higher relapse rates with pharmacotherapy, long-term cost-effectiveness becomes a key issue. In a cost-effective-ness analysis of several outcome studies on depression, that over a2-year period, fluoxetine alone resulted in 33% higher expected costs than individual cognitive behavior therapyand the combination treatment resulted in 23% higher costs than cognitive behavior therapy alone.
ed a meta-analysis of CT of depressive symptoms in adolescents.
There are far fewer studies of CT with this population and most studies have rather small sample sizes. Thereported effect sizes do suggest that CT is superior to wait list, relaxation therapy, and supportive therapy at endof treatment. However, conclusions from this meta-analysis should be considered preliminary. This is especiallytrue given that a recent multi-site controlled trial found that CBT was equivalent to pill-placebo for reduction ofdepressive symptoms in adolescents (T2004).
Presented next are the follow-up findings, where available, for the studies described above. The effectiveness of CBT in preventing relapse of depression was evaluated by n their meta-analysis, theyexamined a subset of eight studies that compared relapse rates for CBT versus antidepressants at least a year afterdiscontinuation of treatment. They concluded that CBT was associated with a bpreventativeQ effect in five of the eightstudies. On average, only 29.5% of CBT patients relapsed versus 60% of patients treated with antidepressants. In thetreatment of depressed adolescents, that the superiority of CT to wait list, relaxation, andsupportive therapy was maintained at 6–12 weeks follow-up.
Additionally, to augment these findings, we have included follow-up findings from recent comprehensive reviews and large-scale trials. n their review of treatment efficacy, obtained highlysimilar figures by averaging 1-year relapse rates across three large-scale clinical trials, finding a substantial differencebetween CT (26%) and pharmacotherapy (64%). mined whether16 sessions of CBT wouldhelp prevent relapse among depressed patients who had responded partially to pharmacotherapy. They found that thecumulative relapse rate at 68 weeks was significantly lower for antidepressant plus CBT patients. Recently, a largemulti-site clinical trial found that cognitive therapy had an enduring effect for moderate-to-severely depressed patientsthat extended beyond the end of treatment and was equivalent to the effect of keeping patients on antidepressantmedication (see In this study, patients who responded to cognitive therapy in a randomizedcontrolled trial (e withdrawn from treatment and compared during a 12-month period withmedication responders who had been randomly assigned to either continuation medication or placebo withdrawal.
Patients withdrawn from CT were significantly less likely to relapse during the 12-month follow-up period thanpatients withdrawn from medications (31% versus 76%), and no more likely to relapse than patients who kept takingcontinuation medication (31% versus 47%).
The effectiveness of CT for generalized anxiety disorder was recently investigated in a meta-analysis by Otto, Pollack, and Yap (1997). Again, the number of studies is small and future replication with more studies isneeded. The preliminary results are strong, with CT being substantially superior to wait list or no-treatment controls,nondirective therapy, and pill placebo. Gould et al. reported that CT and pharmacotherapy showed similar levels ofimprovement from pre- to post-treatment (ESu = 0.70 and 0.61, respectively). Benzodiazepines (ESu = 0.70) were themost commonly evaluated medications in these clinical trials.
With respect to long-term outcome, Gould et al. ( et al., 1997) found that CBT treatment effects were maintained through at least 6 months post-treatment (ES = 0.05).
These results were not available for pharmacotherapy due to a lack of long-term outcome data. Cristoph’s (1998) review of GAD clinical trials found a robust persistence of effects for CT over 3, 6 and 12 months.
Additionally recent reports indicate a persistence of CT effects as far as 8–10 years post-treatment (MacDonald, Power, & Major, 2003). Moreover, in general, CT has demonstrated stronger long-term effects relative toother treatments. One trial, for example, reported that 58% of CT evidenced clinically significant change at 12-monthfollow-up, compared with 38% for applied relaxation ( A.C. Butler et al. / Clinical Psychology Review 26 (2006) 17–31 The outcome findings on CT for panic disorder are supportive and robust. ed a meta-analysis comparing cognitive interventions with exposure treatments and various control conditions. Amongthe cognitive-behavioral treatments, those that combined cognitive restructuring with interoceptive exposureshowed the strongest effect (ES = 0.88). This combination of interventions is the standard CBT approach totreating panic disorder. Cognitive-behavioral treatments in general had the highest effect size (ES = 0.68)compared to pharmacological treatments (ES = 0.47) or combination treatments (ES = 0.56). Perhaps most impres-sive is that the CBT treatment showed virtually no bslippageQ in effect size, (À0.07) by 1-year follow-up ascompared to sizable slippage (À 0.46) for pharmacological treatment. Importantly, there was also a significantlylower attrition rate among cognitive-behavioral treatments (5.6%) compared to pharmacological treatments(19.8%).
red panic patients’ scores at the end of treatment and at follow-up against community norms. They computed effect sizes by subtracting the treatment group mean from the community mean and thendividing by the community standard deviation. They found that CT reduced symptoms to levels near or below thosefound in the general population by end of treatment and these treatment gains were maintained over an unspecifiedfollow-up interval.
Cognitive-behavioral treatments for social phobia have been subjected to meta-analysis twice in recent years (The most recent and extensive meta-analysis by Gouldet al. replicated the findings of Feske and Chambless showing that CT was superior to wait-list and placebo attentioncontrols (ES = 0.93), and similar to exposure interventions without cognitive restructuring (ES = 0.89) and thecombination of the two interventions (ES = 0.80). They found that the average ES for pharmacological interventionswas 0.62, with selective serotonin reuptake inhibitors (ES = 1.89) superior to benzodiazepines (ES = 0.72). Neithermeta-analysis reports on long-term effects of social phobia treatments. However, report that gains were maintained over the long-term in five out of the five large clinical trails reviewed.
Exposure with response prevention (ERP) is sometimes considered the psychological treatment of choice for obsessive-compulsive disorder, but there is growing evidence that CBT is equally effective (Ameta-analysis conducted by that cognitive or cognitive-behavioral treatments forOCD led to substantial reductions in OCD symptoms as rated by patients (ESu = 1.30) and clinical assessors(ESu = 1.86). Furthermore, these treatment effects tended to persist at 6-month and even 12-month follow-ups.
that the effect sizes of the four direct comparisons of cognitive-behavior therapy withERP suggest no difference between the treatments. More recently, in a controlled clinical trial, a combined treatment(cognitive therapy plus ERP) was found to confer clinical gains over and above ERP alone in the treatment ofmedication-refractory OCD ( The National Collaborating Centre for Mental Health in Great Britain recently completed a rigorous meta-analytic review of the clinical research literature on PTSD. Commissioned by the National Institute for Clinical Excellence(NICE), this meta-analysis served as the basis for the National Clinical Practice Guideline on PTSD (Royal College ofPsychiatrists & The British Psychological Society, 2005). The studies reviewed on trauma-based CBT covered a range ofpatient populations including survivors of accidents, assault, sexual assault (including childhood sexual assault),domestic violence, military combat, dmixedT trauma groups and refugees with multiple traumatic events. Overall, thefindings showed clinically important benefits for trauma-focused CBT over wait list control groups on all measures ofPTSD symptoms (mean ES = 1.49). There was also evidence that trauma-focused CBT has clinically significant effectson depression and anxiety in these patients. The other treatment supported by the review was eye-movement A.C. Butler et al. / Clinical Psychology Review 26 (2006) 17–31 desensitization and reprocessing (EMDR). The reviewers note that both trauma-focused CBT and EMDR specificallyaddress the PTSD sufferers’ troubling memories of a traumatic event and the personal meanings of the event and itsconsequences. The meta-analysis also found that direct comparisons of these two approaches did not reveal anysignificant advantages for one over the other, with respect to either treatment outcome or the speed of therapeutic change.
While pharmacotherapy is the front-line treatment for schizophrenia, adjunctive treatments are needed since antipsychotic medications may not be sufficiently effective (noncompliance is a common problem(wed 15 early studieson cognitive and behavioral interventions for delusions and hallucinations. Their summary indicated that CBT producedsignificant reductions in these symptoms. Since Bouchard et al.’s review there have been five randomized clinical trialspublished on CBT of schizophrenia. wed this emerging literature and reported effect sizes.
They concluded that CBT plus routine care (pharmacotherapy and case management) led to substantial pretreatment–posttreatment improvements in positive symptoms, negative symptoms, and total symptoms (grand mean ES = 1.23).
Patients receiving only routine care did much less well (grand mean ES = 0.17). Alternative psychosocial interventions,such as supportive therapy or befriending, produced intermediate results (grand mean ES = 0.60).
results from seven controlled trials of CT for schizophrenia, performed a meta-analysis on the effects of CT on psychotic symptoms. The intervention consisted of targeted CBTstrategies for modifying patients’ distorted beliefs about delusions and hallucinations so as to decrease the negativeconsequences of these symptoms on their daily functioning. They found a large effect size for reduction in psychoticsymptoms between pre- and post-treatment (grand mean ES = 0.65). Of the seven studies, five reported significantdifferences in psychotic symptoms between the control and treatment conditions at post-treatment. The remaining twostudies found non-significant decreases in psychotic symptoms.
With respect to follow-up findings, that across five studies, the follow-up effect size for change in frequency of and distress associated with delusions and hallucinations was large between pretestand follow-up (ES = 1.48) and increased from treatment termination to follow-up. Similarly, large effect sizes werefound for change in the magnitude of negative symptoms at 9-month follow-up across three studies (ES = 0.88).
Also, the small-to-moderate follow-up effect size for change in negative symptoms in the supportive therapy/regular care condition decreased between treatment termination and follow-up (from ES = 0.47 to ES = 0.22). Incontrast, the effect size for the CBT condition, despite decreasing, remained large (ES = 0.88) at follow-up. Similarto these findings, ed that in the four studies providing long-term follow-up findings, thegains made by patients who received CT were maintained and even increased in magnitude (ES = 0.93).
cted a meta-analytic review of marital therapy outcome research. They found a post-treatment ES of 0.71 for cognitive-behavioral marital therapy (CBMT) when compared to no treatment. Thiseffect size was not significantly different from that of behavior marital therapy (BMT; ES = 0.78) but was significantlyless than that of interpersonally oriented marital therapy (IOMT; ES = 1.37). The differences in effectiveness betweenCBMT, BMT, and IOMT narrowed at follow-up and were not statistically significant (ES’s = 0.54, 0.54, and 1.04,respectively). With respect to behavior change in treated couples, there were no significant differences in effect sizesfor BMT, CBMT, and IOMT (ES = 0.79, 0.54, and 0.87, respectively). Similarly, no significant differences were foundat follow-up (ES = 0.52, 0.75, 0.69), though it is interesting to note that the observed effect size for CBMT increasedbetween termination and follow-up.
wed 50 outcome studies on anger covering a total of 1640 subjects, many of whom were in programs for violent offenders. They found a mean weighted effect size of 0.70 for cognitive-behavioral therapy versus untreated controls. The average cognitive-behavioral therapy patients did better than 76%of untreated subjects on reduction of anger.
A.C. Butler et al. / Clinical Psychology Review 26 (2006) 17–31 ned 54 comparisons in their meta-analysis of psychosocial and pharma- cological treatments for bulimia nervosa. They found that CBT was associated with substantial improvements ineating disordered behaviors and eating attitudes. Improvements with CBT were significantly larger than those formedication in terms of binge frequency, purge frequency, and eating attitudes (medication ESu’s = 0.66, 0.39, and0.71, respectively). Parenthetically, there are very few controlled studies on cognitive-behavioral treatment foranorexia nervosa. While the cognitive-behavioral approach appears promising (see ameta-analysis for this disorder is premature.
and meta-analyzed 22 studies that used what they referred to as bself- controlQ interventions in treating children with depressive, anxious, or somatic disorders. These authors used the termbself-control therapyQ as a synonym for cognitive-behavioral therapy and, in particular, for interventions bthat targetchildren’s distorted or deficient cognitive processing or teach coping responsesQ (p. 231). They found self-controltherapy to be superior to no-treatment or placebo controls for depressive, anxious, and somatic disorders in children.
The average primary effect size (0.74) was relatively large, and 77% of effects included were from studies measuringoutcomes at follow-up (average duration = 26 weeks).
One of the more important outcome variables for sexual offenders is recidivism. ed a meta-analysis of 12 recent treatment studies, 5 of which used a cognitive-behavioral approach. The subjects in thesefive studies included adults and adolescents charged with rape, attempted rape, or child molestation. Recidivism wasdefined somewhat differently across studies but all studies used official records to determine recidivism. The meaneffect size of CBT compared to no treatment was 0.35, equal to that of hormonal therapy, and superior to behavioraltherapy. Moreover, CBT showed lower refusal and drop out rates than hormonal treatments. While the CBT effectsizes were relatively small, given the impact on victims, it is arguable that any reduction in sexual offender recidivismis clinically meaningful. Of note, recidivism was measured from 1 year to as many as 28 years (mean = 1.5 years)post-treatment, indicating long-lasting CT effects.
In a recent meta-analysis, 25 trials in which the effective- ness of cognitive treatments for pain (not headache) was compared to wait list and alternative control conditions.
They categorized dependent measures into domains including (a) pain experience, (b) mood, (c) cognitive copingand appraisal, (d) pain behavior/reduced activity, and (e) social role functioning. Cognitive treatments weresignificantly superior to waiting list on all domains except the expression of pain behavior, with a weightedgrand mean ES of 0.46. Across domains, the effect sizes for cognitive treatments were generally larger than thosefor behavior therapy, although there were fewer trials with behavior therapy. There were too few studies usingbiofeedback to make statistical comparisons of effect sizes with CBT. However, the effects sizes reported byMorley et al. for biofeedback, in the area of 0.70, suggest that this is a promising intervention for chronic pain.
When CBT was compared to a heterogeneous collection of alternative treatments (not including behavior therapyor biofeedback), it was found to be superior in reducing pain experience, increasing positive cognitive coping andappraisal, and reducing behavioral expression of pain. No data are reported concerning long-term effectiveness oftreatment.
In this review of 16 recent meta-analyses we sought to answer a multifaceted question: How effective is CBT, for which disorders, and compared to what, and how lasting are these effects? Collectively, the findings detailed in A.C. Butler et al. / Clinical Psychology Review 26 (2006) 17–31 this review suggest that CT is highly effective for adult unipolar depression, adolescent unipolar depression,generalized anxiety disorder, panic disorder with or without agoraphobia, social phobia, PTSD, and childhooddepressive and anxiety disorders. The comparison-weighted grand mean effect size for these disorders whencompared to no-treatment, wait list, or placebo controls is 0.95 (SD = 0.08). CBT is associated with largeimprovements in symptoms for bulimia nervosa, and the associated effect sizes (M = 1.27, SD = 0.11) are signif-icantly larger than those that have been found for pharmacotherapy. CBT also has shown promising results as anadjunct to pharmacotherapy in the treatment of schizophrenia. The average uncontrolled effect size of 1.23 for CBTcompares favorably with an ES of 0.17 for schizophrenic patients receiving only routine care. Moderate effect sizes(M = 0.62, SD = 0.11) were obtained when CT was compared to controls for marital distress, anger, childhoodsomatic disorders, and several chronic pain variables (i.e., pain expression behavior, activity level, social rolefunctioning and cognitive coping and appraisal). CT was somewhat superior to antidepressants in the treatment ofadult unipolar depression (ES = 0.38). CT was equally effective to behavior therapy in the treatment of adultdepression (ES = 0.05) as well as obsessive-compulsive disorder (ES = 0.19). Trauma-focused CBT and EMDR wereequally effective for PTSD. The efficacy of CT for sexual offending is relatively low (ES = 0.35). However, alongwith hormonal treatments, it is the most effective treatment for reducing recidivism in this population. Finally, CTwas found to be superior to supportive/nondirective therapy in the few occurrences when these two treatments weredirectly compared. This includes two comparisons for adolescent depression (ES = 0.84) and two comparisons forgeneralized anxiety disorder (ES = 0.71).
We also aimed to provide answers regarding the degree to which the effects of CT persist following the termination of treatment. The meta-analyses reviewed strongly suggest that across many disorders the effects of CT aremaintained for substantial periods beyond the cessation of treatment. More specifically, significant evidence forlong-term effectiveness was found for depression, generalized anxiety, panic, social phobia, OCD, sexual offending,schizophrenia, and childhood internalizing disorders. In the cases of depression and panic, there appears to be robustand convergent meta-analytic evidence that CT produces vastly superior long-term persistence of effects, with relapserates half those of pharmacotherapy. In addition, CT appears to show greater long-term effects in the treatment ofgeneralized anxiety disorder as compared to applied relaxation.
This review of existing meta-analyses adds to our knowledge of the effects of CT for a variety of disorders.
However, future meta-analyses should (1) continue to evaluate the effects of CBT as applied to an even wider, morespecific spectrum of disorders, (2) continue to evaluate the long-term effects of CBT, and (3) continue to evaluate theeffects of CBT as compared to alternative treatments. For example, with respect to the former, n arandomized controlled trial of CBT for relapse prevention in Bipolar Disorder, found that patients treated with CBTexperienced significantly better outcomes (e.g., fewer and shorter bipolar episodes, fewer hospital admissions, lessvariability in manic symptoms, etc.) at 1 year follow-up. However, because there are currently no meta-analyticfindings on CBT for Bipolar Disorder, the application of meta-analytic procedures will make an important contri-bution as similar studies are completed.
Similarly, for many disorders the current review offers little to no evidence bearing on the question of the persistence of CBT effects relative to other psychological and pharmacological interventions. The degree to whichCBT is or is not superior to alternative treatments in terms of follow-up findings has only been partially addressed bythe meta-analyses reviewed here. For example, limited findings were available on the long-term effects of CBT foranger, bulimia, anorexia nervosa, and chronic pain. The current evidence, where available, does suggest a generaladvantage in favor of CBT. For disorders lacking such findings, we incorporated recent reviews of CBT. For example,the review by ded additional support for the long-term efficacy of CBT fordepression, GAD, and social phobia.
Clearly, more research is needed comparing CBT with other forms of therapy. Indeed, the effect sizes we reported comparing CBT to other active treatments for adolescent depression, generalized anxiety disorder, panic disorder, andobsessive-compulsive disorder must be considered preliminary due to the low number of studies in the correspondingmeta-analyses. We included these meta-analyses in this review since the effect sizes reported provide a starting pointfor evaluating the stability of results across samples, designs, and analyses. Such information also informs poweranalyses for future primary studies ( Future meta-analyses will continue to face the challenges associated with long-term findings such as variable follow-up assessment time-points across studies and the handling of data for patients who drop out of studies duringthe follow-up period (Despite these obstacles, the examination of long-term effects has critical A.C. Butler et al. / Clinical Psychology Review 26 (2006) 17–31 implications for the viability of treatments, treatment recommendations and decision making, and the determination ofcost-benefit ratios and economic efficiency.
Meta-analysis has gained increasing recognition as a valid procedure for evaluating the efficacy of a treatment (However, the limitations of this approach should be kept in mind whendrawing conclusions from this review. The practice of reporting multiple effect sizes for individual studies isproblematic since these are typically not independent. This makes it likely that some of the studies are given moreweight than others. Also, simply aggregating effect sizes may mask important variability among studies inmethodological rigor, sample characteristics, and measurement instruments and procedures. In some cases, suchfactors can be quantitatively assessed and incorporated into a meta-analysis as moderator variables. Where possible,we reported results on important moderator variables that have been studied meta-analytically (e.g., researcherallegiance in depression studies). However, inclusion of moderator variables was not generally the case in the meta-analyses we reviewed. Another limitation of averaging effect sizes is that striking successes and failures may beoverlooked and these are important in interpreting outcome findings. In this respect, it is important to note that theconclusions from this meta-analysis review are consistent with recent reviews of high-quality primary studies( There has been a trend since the 1970s to apply CBT to an increasingly wider spectrum of disorders ( Substance abuse, bipolar disorder, personality disorders, and anorexia nervosa are among the disorders receivingrecent empirical attention. As additional controlled outcome studies accumulate, future meta-analyses will be neededto examine the strength of CT in the treatment of these and other disorders.
Abramowitz, J. S. (1997). Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: A quantitative review.
Journal of Consulting and Clinical Psychology, 65, 44 – 52.
Antonuccio, D. O., Thomas, M., & Danton, W. G. (1997). A cost-effectiveness analysis of cognitive behavior therapy and fluoxetine (prozac) in the treatment of depression. Behavior Therapy, 28, 187 – 210.
Beck, A. T. (1997). The past and future of cognitive therapy. Journal of Psychotherapy Practice and Research, 6, 276 – 284.
Beck, J. S. (1995). Cognitive therapy: Basics and beyond. New York7 Guilford Press.
Beck, R., & Fernandez, E. (1998). Cognitive-behavioral therapy in the treatment of anger: A meta-analysis. Cognitive Therapy and Research, 22, Beutler, L. E. (2002). The dodo bird is extinct. Clinical Psychology: Science & Practice, 9, 30 – 34.
Blackburn, I. M., Bishop, S., Glen, A. I., Whalley, L. J., & Christie, J. E. (1981). The efficacy of cognitive therapy in depression: A treatment trial using cognitive therapy and pharmacotherapy, each alone and in combination. British Journal of Psychiatry, 139, 181 – 189.
Blatt, S. J., Zuroff, D. C., Bondi, C. M., & Sanislow, C. A. (2000). Short- and long-term effects of medication and psychotherapy in the brief treatment of depression: Further analyses of data from the NIMH TDCRP. Psychotherapy Research, 10(2), 215 – 234.
Borkovec, T. D., & Costello, E. (1993). Efficacy of applied relaxation and cognitive-behavioral therapy in the treatment of generalized anxiety disorder. Journal of Consulting and Clinical Psychology, 61, 611 – 619.
Bouchard, S., Vallieres, A., Roy, M. A., & Maziade, M. (1996). Cognitive restructuring in the treatment of psychotic symptoms in schizophrenia: A critical analysis. Behavior Therapy, 27, 257 – 277.
Chambless, D. L. (2002). Beware the dodo bird: The dangers of overgeneralization. Clinical Psychology: Science & Practice, 9, 13 – 16.
Cohen, J. (1988). Statistical power analysis for the behavioral sciences (2nd ed.). Hillsdale, NJ7 Erlbaum.
Cooper, H. M., & Hedges, L. V. (1994). The handbook of research synthesis. New York7 Russell Sage Foundation.
DeRubeis, R. J., & Crits-Christoph, P. (1998). Empirically supported individual and group psychological treatments for adult mental disorders.
Journal of Consulting and Clinical Psychology, 66, 37 – 52.
DeRubeis, R. J., Hollon, S. D., Amsterdam, J. D., Shelton, R. C., Young, P. R., Salomon, R. M., et al. (2005). Cognitive therapy vs. medications in the treatment of moderate to severe depression. Archives of General Psychiatry, 62, 409 – 416.
Dobson, K. S. (1989). A meta-analysis of the efficacy of cognitive therapy of depression. Journal of Consulting and Clinical Psychology, 57, Dobson, K. S. (Ed.). (2001). Handbook of cognitive-behavioral therapies, (2nd ed.). New York7 Guilford Press.
Dobson, K. S., & Dozois, D. J. (2001). Historical and philosophical bases of the cognitive-behavioral therapies. In K. S. Dobson (Ed.), Handbook of cognitive-behavioral therapies (2nd ed.). New York7 Guilford Press.
Dunn, R. L., & Schwebel, A. I. (1995). Meta-analytic review of marital therapy outcome research. Journal of Family Psychology, 9, Durham, R. C., Chambers, J. A., MacDonald, R. R., Power, K. G., & Major, K. (2003). Does cognitive-behavioural therapy influence the long-term outcome of generalized anxiety disorder? An 8–14 year follow-up of two clinical trials. Psychological Medicine, 33, 499 – 509.
Elkin, I., Shea, M. T., Watkins, S. D., Imber, S. M., Sotsky, S. M., Collins, D. R., et al. (1989). National Institute of Mental Health treatment of depression collaborative research program: General effectiveness of treatments. Archives of General Psychiatry, 46, 971 – 982.
A.C. Butler et al. / Clinical Psychology Review 26 (2006) 17–31 Feske, U., & Chambless, D. L. (1995). Cognitive behavioral versus exposure only treatment for social phobia: A meta-analysis. Behavior Therapy, Gaffan, E. A., Tsaousis, I., & Kemp-Wheeler, S. M. (1995). Research allegiance and meta-analysis: The case of cognitive therapy for depression.
Journal of Consulting and Clinical Psychology, 63, 966 – 980.
Glass, G. V., McGraw, B., & Smith, M. L. (1981). Meta-analysis in social research. Beverly Hills, CA7 Sage.
Gloaguen, V., Cottraux, J., Cucherat, M., & Blackburn, I. (1998). A meta-analysis of the effects of cognitive therapy in depressed patients. Journal of Affective Disorders, 49, 59 – 72.
Gould, R. A., Buckminster, S., Pollack, M. H., Otto, M. W., & Yap, L. (1997). Cognitive-behavioral and pharmacological treatment for social phobia: A meta-analysis. Clinical Psychology: Science & Practice, 4, 291 – 306.
Gould, R. A., Mueser, K. T., Bolton, E., Mays, V., & Goff, D. (2001). Cognitive therapy for psychosis in schizophrenia: An effect size analysis.
Schizophrenia Research, 48, 335 – 342.
Gould, R. A., Otto, M. W., & Pollack, M. H. (1995). A meta-analysis of treatment outcome for panic disorder. Clinical Psychology Review, 15(8), Gould, R. A., Otto, M. W., Pollack, M. H., & Yap, L. (1997). Cognitive behavioral and pharmacological treatment of generalized anxiety disorder: A preliminary meta-analysis. Behavior Therapy, 28, 285 – 305.
Grossman, P. B., & Hughes, J. N. (1992). Self-control interventions with internalizing disorders: A review and analysis. School Psychology Review, Hollon, S. D., & Beck, A. T. (1994). Cognitive and cognitive-behavioral therapies. In A. E. Bergin, & S. L. Garfield (Eds.), Handbook of psychotherapy and behavior change, (4th ed.) (pp. 428–466).
Hollon, S. D., DeRubeis, R. J., Shelton, R. C., Amsterdam, J. D., Salomon, R. M., & O’Reardon, J. P., et al. (2005). Prevention of relapse following cognitive therapy vs. medications in moderate to severe depression. Archives of General Psychiatry, 62, 417 – 422.
Hollon, S. D., Thase, M. E., & Markowitz, J. C. (2002). Treatment and prevention of depression. Psychological Science in the Public Interest, 3, Howard, K. I., Krause, M. S., Saunders, S. M., & Kopta, S. M. (1997). Trials and tribulations in the meta-analysis of treatment differences: Comment on Wampold et al. (1997). Psychological Bulletin, 122, 221 – 225.
Lam, D. H., Watkins, E. R., Harward, P., Bright, J., Wright, K., & Kerr, N., et al. (2003). A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder: Outcome of the First Year. Archives of General Psychiatry, 60(2), 145 – 152.
Luborsky, L., Rosenthal, R., Diguer, L., Andrusyna, T. P., Berman, J. S., Levitt, J. T., et al. (2002). The dodo bird verdict is alive and well-mostly.
Clinical Psychology: Science & Practice, 9, 2 – 12.
Messer, S. B., & Wampold, B. E. (2002). Let’s face facts: Common factors are more potent than specific therapy ingredients. Clinical Psychology: Science & Practice, 9, 21 – 25.
Morley, S., Eccleston, C., & Williams, A. (1999). Systematic review and meta-analysis of randomized controlled trials of cognitive behaviour therapy and behaviour therapy for chronic pain in adults, excluding headache. Pain, 80, 1 – 13.
Nagayama Hall, G. C. (1995). Sexual offender recidivism revisited: A meta-analysis of recent treatment studies. Journal of Consulting and Clinical Nathan, P. E., & Gorman, J. M. (1998). A guide to treatments that work. Oxford7 Oxford University Press.
Oei, T. P. S., Llamas, M., & Devilly, G. J. (1999). The efficacy and cognitive processes of cognitive behaviour therapy in the treatment of panic disorder with agoraphobia. Behavioural and Cognitive Psychotherapy, 27, 63 – 88.
Olfson, M., & Klerman, G. L. (1993). Trends in the prescription of antidepressants by office-based psychiatrists. American Journal of Psychiatry, Parker, G., Roy, K., & Eyers, K. (2003). Cognitive behavior therapy for depression? Choose horses for courses. American Journal of Psychiatry, Paykel, E. S., Scott, J., Teasdale, J. D., Johnson, A. L., Garland, A., Moore, R., et al. (1999). Prevention of relapse in residual depression by cognitive therapy: A controlled trial. Archives of General Psychiatry, 56, 829 – 835.
Ratakonda, S., Miller, C. E., Gorman, J. M., & Sharif, Z. A. (1997). Efficacy of a 12-week trial of olanzapine in treatment of refractory schizophrenia or schizoaffective disorder. Schizophrenia Bulletin, 29, 151.
Rector, N. A., & Beck, A. T. (2001). Cognitive-behavioral therapy for schizophrenia: An empirical review. Journal of Nervous and Mental Disease, Rector, N. A., Richter, M. A., Denisoff, E., Crawford, C., Szacun-Shimizu, K., Bourdeau, D. (2005). Cognitive and behavioral treatments for Reinecke, M. A., Ryan, N. E., & DuBois, D. L. (1998). Cognitive-behavioral therapy of depression and depressive symptoms during adolescence: A review and meta-analysis. Journal of the American Academy of Child and Adolescent Psychiatry, 37(1), 26 – 34.
Rounsaville, B. J., & Carroll, K. M. (2002). Commentary on dodo bird revisited: Why aren’t we dodos yet? Clinical Psychology: Science & Rush, A. J., Beck, A. T., Kovacs, M., & Hollon, S. D. (1977). Comparative efficacy of cognitive therapy and pharmacotherapy in the treatment of depressed outpatients. Cognitive Therapy and Research, 1(1), 7 – 37.
Salkovskis, P. M. (Ed.). (1996). Frontiers of cognitive therapy. New York7 Guilford Press.
Shapiro, D. A., Barkham, M., Rees, A., Hardy, G. A., Reynolds, S., & Startup, M. (1994). Effects of treatment duration and severity of depression on the effectiveness of cognitive-behavioral and psychodynamic-interpersonal psychotherapy. Journal of Consulting and Clinical Psychology,62, 522 – 534.
Simons, A. D., Levine, J. L., Lustman, P. J., & Murphy, G. E. (1984). Patient attrition in a comparative outcome study of depression: A follow-up report. Journal of Affective Disorders, 6, 163 – 173.
A.C. Butler et al. / Clinical Psychology Review 26 (2006) 17–31 Stahl, S. M. (1999). Selecting atypical antipsychotics by combining clinical experience with guidelines from clinical trials. Journal of Clinical Thase, E. M., Greenhouse, J. B., Frank, E., Reynolds, C., Pilkonis, P. A., Hurley, K., et al. (1997). Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. Archives of General Psychiatry, 54, 1009 – 1015.
Treatment for Adolescents With Depression Study (TADS) Team, US. (2004). Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for adolescents with depression study (TADS) randomized controlled trial. Journal of the AmericanMedical Association, 292(7), 807 – 820.
Van Balkom, A. J. L. M., van Oppen, P., Vermeulen, A. W. A., van Dyck, R., Nauta, M. C. E., & Vorst, H. C. M. (1994). A meta-analysis on the treatment of obsessive-compulsive disorder: A comparison of antidepressants, behavior, and cognitive therapy. Clinical Psychology Review, 14,359 – 381.
Wampold, B. E., Minami, T., Baskin, T. W., & Tierney, S. C. (2002). A meta-(re) analysis of the effects of cognitive therapy versus dother therapiesT for depression. Journal of Affective Disorders, 68, 159 – 165.
Whittal, M. L., Agras, W. S., & Gould, R. A. (1999). Bulimia nervosa: A meta-analysis of psychological and pharmacological treatments. Behavior Wilkinson, L. (1999). Statistical methods in psychology journals: Guidelines and explanations. American Psychologist, 54, 594 – 604.
Wilson, G. T., & Fairburn, C. G. (1998). Treatments for eating disorders. In P. E. Nathan, & J. M. Gorman (Eds.), A guide to treatments that work.


Pubblicazioni ssc 1995-2000

Pubblicazioni SSC 1995-2000 1.: Tenore di benzene nelle benzine e sua influenza sulle emissioni degli autoveicoli. Riv. Combustibili, 49, 223 (1995). 2.: Nuovi metodi di misura nell'industria del gas. Riv. Combustibili, 49, 57 (1995). 3.: Solventi e sicurezza. Infiammabilità. Riv. Combustibili, 49, 223 (1995). 4. Emissione di particolato nella combustione di oli: problemi di combustione e

Microsoft word - faqsurgerysept2011.doc

Consultant Orthopaedic Foot & Ankle Surgeon Guy’s and St Thomas’ NHS Foundation Trust 1st Floor, 29 Tooley Street, London SE1 2PR T: 0207 234 2167, 0207 234 2719 F: 0207 234 2030 Email: Website: Frequently asked questions about surgery When and where do I perform surgery? I operate every alternate week at London Bridge on a

Copyright © 2010-2014 Pharmacy Pills Pdf